Related Experiment Videos
[CD2 and CD8 expression in acute promyelocytic leukemia]
Y Kawachi1, A Watanabe, T Nishihara
1Department of Internal Medicine, Takamatsu Red Cross Hospital.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|December 1, 1996
Summary
This case report details a rare microgranular acute promyelocytic leukemia (APL) with CD8 expression. The patient experienced rapid progression and mortality despite intensive treatment, highlighting the need for novel therapeutic strategies.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by specific chromosomal translocations.
- The microgranular variant of APL presents unique morphological and clinical features.
- Standard treatment protocols for APL may require modification based on specific immunophenotypic markers.
Observation:
- A 34-year-old male presented with headache, severe anemia, and a high white blood cell count predominantly composed of myeloblasts.
- Morphological and electron microscopy revealed microgranular features, and cytogenetic analysis identified the characteristic t(15;17) translocation.
- Immunophenotyping showed positivity for CD2, CD8, CD13, and CD33, with CD8 expression being a rare finding in APL.
Findings:
- The patient was diagnosed with the microgranular variant of acute promyelocytic leukemia (APL) with coexisting disseminated intravascular coagulation (DIC).
- Despite aggressive treatment including chemotherapy and supportive care, the patient's condition rapidly deteriorated.
- The presence of CD8 expression on leukemic cells in this APL case is unprecedented.
Implications:
- This case underscores the heterogeneity of APL and suggests that CD8 expression may indicate a distinct clinical or biological subtype.
- Current treatment strategies may be insufficient for APL with CD8 expression, necessitating exploration of modified or novel therapeutic approaches.
- Further research and reporting of similar cases are crucial to establish optimal treatment guidelines for this rare APL variant.